DDInter1548 DDInter1376
Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the early use of [physostigmine] and [neostigmine]. By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.[A231004, L32408, L32413] Pyridostigmine is the current drug of choice, with superior pharmacokinetics and reduced side effects compared to [neostigmine].[L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pyridostigmine {u} (Compound) resembles {v} (Compound) Neostigmine
Pyridostigmine {u} (Compound) binds {v} (Gene) BCHE
Pyridostigmine {u} (Compound) upregulates {v} (Gene) INPP4B
Pyridostigmine {u} (Compound) causes {v} (Side Effect) Cholinergic syndrome
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Pyridostigmine (Compound) resembles Neostigmine (Compound)
Pyridostigmine (Compound) binds BCHE (Gene)
Pyridostigmine (Compound) upregulates INPP4B (Gene)
Pyridostigmine (Compound) causes Cholinergic syndrome (Side Effect)
Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone